Fibrose hépatique
EMC - Hépatologie, ISSN: 1155-1976, Vol: 27, Issue: 4, Page: 1-9
2012
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
La sévérité des maladies chroniques du foie, véritable enjeu de santé publique, est liée à leur caractère fibrosant. Les travaux de recherche effectués ces dernières années ont permis de mieux caractériser les acteurs cellulaires et moléculaires de la fibrose. Ce sont les myofibroblastes hépatiques qui, sous l’influence de facteurs profibrosants tels que le transforming growth factor β ou le platelet-derived growth factor, s’accumulent et synthétisent en excès les composants de la matrice extracellulaire responsables de la fibrose. En pratique clinique, l’évaluation de la fibrose a été améliorée par le développement de méthodes non invasives : les algorithmes de paramètres sériques et l’élastométrie impulsionnelle. La prise en charge thérapeutique de la fibrose comprend le traitement de la cause, le traitement des comorbidités et le traitement antifibrosant. À ce jour, les traitements antifibrosants ne sont administrés qu’au cours d’essais cliniques, mais la richesse des études en cours sur de nouvelles pistes thérapeutiques fait apparaître des traitements ciblés prometteurs pour l’avenir.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1155197612597883; http://dx.doi.org/10.1016/s1155-1976(12)59788-3; https://linkinghub.elsevier.com/retrieve/pii/S1155197612597883; http://linkinghub.elsevier.com/retrieve/pii/S1155197612597883; http://api.elsevier.com/content/article/PII:S1155197612597883?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S1155197612597883?httpAccept=text/plain; http://dx.doi.org/10.1016/s1155-1976%2812%2959788-3; https://dx.doi.org/10.1016/s1155-1976%2812%2959788-3
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know